DPP-26 CN Export – Wholesale

200 - 2700

DPP-26: Innovative Opioid Analgesic

Overview: DPP-26 is a cutting-edge opioid analgesic designed to manage severe pain effectively. It serves as an alternative for patients who cannot use morphine due to contraindications or allergies.

Key Features:

  • Targeted Pain Relief: By interacting with central nervous system opioid receptors, DPP-26 effectively alleviates severe pain.
  • Alternative to Morphine: Ideal for patients who are allergic to or cannot tolerate morphine.
  • Research Utility: Valuable in laboratory settings for studying opioid properties and pain management mechanisms.

Important Considerations:

  • Potency: Approximately 2.5 times less potent than morphine; dosing should be adjusted accordingly.
  • Safety Profile: Potential side effects may include respiratory depression, sedation, constipation, nausea, and the risk of dependence. Comprehensive clinical data is currently limited.
  • DPP-26 は、お支払い後48時間-72時間で出荷する準備ができています。

    平均納期:1ヶ月

    当ウェブサイトで販売されているすべてのデザイナー・ドラッグは、研究用および法医学用です。

    注意!
    IN CASE OF LOSS, WRONG ADDRESS OR ANY OTHER ISSUE, FOR THIS PRODUCT IS NOT ALLOWED ANY RESHIP NOR REFUND

     

DPP-26 is an opioid analgesic developed for managing severe pain, particularly in cases where morphine is contraindicated or patients exhibit allergies to morphine. Its chemical designation is 1-(4-(ethylsulfonyl)-4,4-diphenylbutan-2-yl)piperidine, with a molecular formula of C₂₃H₃₁NO₂S and a molecular weight of 385.6 g/mol. The compound appears as a crystalline solid and is soluble in solvents such as acetone and DMSO.

Mechanism of Action and Pharmacodynamics

As an opioid analgesic, DPP-26 functions by binding to opioid receptors in the central nervous system (CNS), mimicking the effects of endogenous opioids. This binding inhibits the transmission of pain signals, leading to analgesia. Notably, DPP-26 exhibits an opioid potency approximately 2.5 times lower than that of morphine, indicating that higher doses may be required to achieve similar analgesic effects.

用法・用量

Specific dosage guidelines for DPP-26 have not been established due to limited clinical data. Given its reduced potency relative to morphine, dosing regimens would likely need adjustment to achieve desired analgesic outcomes. Administration routes, frequency, and titration schedules remain to be determined through comprehensive clinical studies.​ncbi.nlm.nih.gov+6prepwatch.org+6drugs.com+6

薬物動態学

Detailed pharmacokinetic profiles, including absorption, distribution, metabolism, and excretion parameters for DPP-26, are currently unavailable. Understanding these characteristics is essential for optimizing dosing strategies and minimizing potential adverse effects.​

Side Effects and Adverse Reactions

While specific side effects of DPP-26 have not been documented, it is reasonable to anticipate adverse reactions similar to those associated with other opioid analgesics:​

  • Respiratory Depression: Opioids can suppress the respiratory center in the brainstem, leading to decreased respiratory rate and depth.​
  • Sedation: Patients may experience drowsiness or lethargy, affecting their ability to perform tasks requiring alertness.​
  • Constipation: Opioids often reduce gastrointestinal motility, resulting in constipation.​
  • Nausea and Vomiting: Stimulation of the chemoreceptor trigger zone can lead to these gastrointestinal symptoms.​hopkinsguides.com+6mayoclinic.org+6drugs.com+6
  • Physical Dependence: Chronic use may result in tolerance and dependence, with withdrawal symptoms upon abrupt cessation.​

Harm Reduction and Safety Considerations

To mitigate potential risks associated with DPP-26 use, the following harm reduction strategies are recommended:​

  • Medical Supervision: Ensure that DPP-26 is prescribed and monitored by healthcare professionals experienced in opioid management.​
  • Patient Education: Inform patients about the potential risks, proper usage, and signs of adverse reactions.​drugs.com
  • Titration: Initiate treatment at the lowest effective dose, with gradual adjustments based on patient response and tolerability.​
  • Monitoring: Regularly assess respiratory function, mental status, and signs of misuse or dependence.​
  • 禁忌: Avoid use in patients with known hypersensitivity to opioids or those with conditions contraindicating opioid therapy.​

Legal and Regulatory Status

The legal status of DPP-26 varies across jurisdictions. In many countries, its status remains unclear, necessitating that it be used strictly for chemical research in specially equipped laboratories, adhering to all regulations and safety measures.

結論

DPP-26 represents a novel opioid analgesic with potential applications in pain management, especially for patients unable to tolerate morphine. However, due to limited clinical data, its safety, efficacy, and pharmacokinetic properties are not well-defined. Comprehensive research and clinical trials are essential to establish appropriate dosing regimens, identify potential adverse effects, and develop harm reduction strategies to ensure patient safety.


なぜ買うのか DPP-26 CN RECHEMCOから?

私たちは市場で長い取引の歴史を持っているので、あなたは私たちの経験から利益を得ることができます。
★ DPP-26 がテストされ、検証された。
ビットコイン、モネロ、銀行送金など、さまざまなお支払い方法をご利用いただけます。

ご購入時にお渡しするもの DPP-26 RECHEMCOから?

- 最高級のアルミ箔入り密封袋1袋 DPP-26
• crystalline powder
- 99% 純度

数量

5g、10g、25g、50g、100g、250g

レビュー

レビューはまだありません。

“DPP-26 CN Export – Wholesale” の口コミを投稿します

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

スピン・トゥ・ウィン

  • あなたの運を試して、割引クーポンコードを獲得しよう
  • 15日ごとに1回のフリースピン
  • 不正行為は禁止です!メールアドレスは実在するものを使用してください。
  • 注意:クーポンコードの有効期限は7日間です。
運試し!
決して
後で知らせる
遠慮する